242 related articles for article (PubMed ID: 19915299)
1. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
3. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
[TBL] [Abstract][Full Text] [Related]
5. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
7. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
8. On being metachromatic: mystique and misunderstanding in mastocytosis.
Gotlib J
Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
[No Abstract] [Full Text] [Related]
9. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
10. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Vega-Ruiz A; Cortes JE; Sever M; Manshouri T; Quintás-Cardama A; Luthra R; Kantarjian HM; Verstovsek S
Leuk Res; 2009 Nov; 33(11):1481-4. PubMed ID: 19193436
[TBL] [Abstract][Full Text] [Related]
11. Skin lesions and mast cells.
Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
[No Abstract] [Full Text] [Related]
12. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
13. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
14. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
17. Treatment of systemic mast cell disease: beyond interferon.
Tefferi A
Leuk Res; 2004 Mar; 28(3):223-4. PubMed ID: 14687615
[No Abstract] [Full Text] [Related]
18. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
19. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilia in mast cell disease.
Kovalszki A; Weller PF
Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
